Markus Eckstein - Concepedia

Author

Markus Eckstein

Friedrich-Alexander-Universität Erlangen-Nürnberg ORCID

Also Known As

Almudena Espin Perez, Eckstein, M., Eckstein, Markus, M ECKSTEIN, M Eckstein, M. B. Eckstein, M. Eckstein, M. Morgan, M., Eckstein, Marc Eckstein

557

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Friedrich-Alexander-Universität Erlangen-Nürnberg Universitätsklinikum Erlangen Comprehensive Cancer Center Erlangen University of Regensburg Heidelberg University

About

Markus Eckstein is an author at Friedrich-Alexander-Universität Erlangen-Nürnberg specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	32	1.8K
2	Health Sciences	3	3	54
3	Engineering	2	2	92
4	Biomedical Engineering	2	2	92
5	Biostatistics	1	1	237

Markus Eckstein

131

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Multistain deep learning for prediction of prognosis and therapy response in colorectal cancer Sebastian Foersch, Christina Glasner, Ann-Christin Woerl, Nature Medicine MedicineTherapy ResponsePrognosisPathologyColorectal Cancer	2023	237
The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes Carolin Pfannstiel, Pamela L. Strissel, Katherine B. Chiappinelli, Cancer Immunology Research ImmunologyBiological MicroenvironmentsPathologyImmunoeditingImmunotherapy	2019	224
Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides Ann-Christin Woerl, Markus Eckstein, Josephine Geiger, European Urology UrologyGenitourinary CancerTumor HeterogeneityMedicineSurgical Pathology	2020	174
Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. Shilpa Gupta, Guru Sonpavde, Christopher Weight, Journal of Clinical Oncology Radical CystectomySurgical OncologyUrologyPd-l1 ExpressionGenitourinary Cancer	2020	134
Bispecific T cell engager therapy for refractory rheumatoid arthritis Laura Bucci, Melanie Hagen, Tobias Rothe, Nature Medicine Rheumatoid DisorderRheumatologyAutoimmune DiseaseImmunologyAutoimmunity	2024	121
Deep learning for diagnosis and survival prediction in soft tissue sarcoma Sebastian Foersch, Markus Eckstein, Daniel‐Christoph Wagner, Annals of Oncology	2021	115
CD19-CAR T-cell therapy induces deep tissue depletion of B cells Carlo Tur, Markus Eckstein, Joachim Velden, Annals of the Rheumatic Diseases	2024	110
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab Markus Eckstein, Philipp Erben, Maximilian C. Kriegmair, European Journal of Cancer UrologyGenitourinary CancerTherapy StratificationUrothelial CarcinomaMedicine	2018	100
EMT transcription factor ZEB1 alters the epigenetic landscape of colorectal cancer cells Pablo Lindner, Sushmita Paul, Markus Eckstein, Cell Death and Disease Epigenetic ChangeDna MethylationCancer BiologyEpigeneticsTumor Biology	2020	96
<i>NECTIN4</i> Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Journal of Clinical Oncology	2024	95

Page 1